Thus, future studies with larger sample sizes, including novel types of non-metformin oral antidiabetics than those investigated herein (e.g., dipeptidyl-peptidase 4 inhibitors, glucagon-like peptide-1 receptor agonists), are needed to advance our understanding of how oral antidiabetics impact sleep among patients with T2D. The gene discussed is DPP4; the disease is type 2 diabetes mellitus.